CN109414474B - 肝脏、胆道和胰腺障碍的治疗 - Google Patents

肝脏、胆道和胰腺障碍的治疗 Download PDF

Info

Publication number
CN109414474B
CN109414474B CN201780039341.1A CN201780039341A CN109414474B CN 109414474 B CN109414474 B CN 109414474B CN 201780039341 A CN201780039341 A CN 201780039341A CN 109414474 B CN109414474 B CN 109414474B
Authority
CN
China
Prior art keywords
defensin
hbd
mice
high fat
liver
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780039341.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN109414474A (zh
Inventor
P·诺德基尔德
S·基亚罗夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novozymes AS
Original Assignee
Novozymes AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novozymes AS filed Critical Novozymes AS
Publication of CN109414474A publication Critical patent/CN109414474A/zh
Application granted granted Critical
Publication of CN109414474B publication Critical patent/CN109414474B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1729—Cationic antimicrobial peptides, e.g. defensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CN201780039341.1A 2016-04-29 2017-04-28 肝脏、胆道和胰腺障碍的治疗 Active CN109414474B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA201670276 2016-04-29
DKPA201670276 2016-04-29
DKPA201670484 2016-07-01
DKPA201670484 2016-07-01
PCT/DK2017/050132 WO2017186250A1 (en) 2016-04-29 2017-04-28 Treatment of liver, biliary tract and pancreatic disorders

Publications (2)

Publication Number Publication Date
CN109414474A CN109414474A (zh) 2019-03-01
CN109414474B true CN109414474B (zh) 2024-07-02

Family

ID=58992579

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780039341.1A Active CN109414474B (zh) 2016-04-29 2017-04-28 肝脏、胆道和胰腺障碍的治疗

Country Status (13)

Country Link
US (1) US12076368B2 (https=)
EP (1) EP3448409B1 (https=)
JP (1) JP2019514908A (https=)
KR (1) KR102465341B1 (https=)
CN (1) CN109414474B (https=)
AU (1) AU2017258242B2 (https=)
BR (1) BR112018071972A2 (https=)
CA (1) CA3022497A1 (https=)
ES (1) ES3057685T3 (https=)
PL (1) PL3448409T3 (https=)
RU (1) RU2740913C2 (https=)
SG (1) SG11201809086YA (https=)
WO (1) WO2017186250A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102244161B1 (ko) * 2018-08-31 2021-04-26 주식회사 나이벡 다중의 질환 바이오마커의 기능 및 발현을 억제하는 펩타이드의 신규한 용도
MX2021008249A (es) 2019-01-07 2021-10-13 Aesculus Bio Aps Fragmentos de defensina para su uso en tratamientos o profilaxis.
CN110279851A (zh) * 2019-07-05 2019-09-27 浙江大学 Defa4细胞因子在制备治疗肝功能衰竭药剂中的应用
CN114058694A (zh) * 2021-11-29 2022-02-18 上海市普陀区中心医院 Trpv1在筛选或制备预防、缓解和/或治疗肝脏疾病的药物中的应用
KR102735773B1 (ko) * 2022-11-10 2024-11-27 을지대학교 산학협력단 혈액 내 단백질 바이오마커를 포함하는 암 진단용 키트

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104971343A (zh) * 2015-07-13 2015-10-14 韩源平 防御素在制备治疗代谢综合征药物方面的应用
CN105504063A (zh) * 2015-10-19 2016-04-20 中国医学科学院医药生物技术研究所 一类防御素-白蛋白的抗肿瘤融合蛋白及其制备和应用
CN108026130A (zh) * 2016-07-30 2018-05-11 邦泰生物工程(深圳)有限公司 一种制备烟酰胺单核苷酸的方法2
CN112795606A (zh) * 2021-04-14 2021-05-14 深圳瑞德林生物技术有限公司 一种β-烟酰胺单核苷酸的酶催化合成方法
CN114075585A (zh) * 2020-08-18 2022-02-22 弈柯莱生物科技(上海)股份有限公司 一种β-烟酰胺单核苷酸的制备方法
CN114107160A (zh) * 2021-12-27 2022-03-01 浙江工业大学 一种烟酰胺核糖激酶基因工程菌及其应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
IL99552A0 (en) 1990-09-28 1992-08-18 Ixsys Inc Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
DE4343591A1 (de) 1993-12-21 1995-06-22 Evotec Biosystems Gmbh Verfahren zum evolutiven Design und Synthese funktionaler Polymere auf der Basis von Formenelementen und Formencodes
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US20040091498A1 (en) 2002-05-31 2004-05-13 Aaron Diamond Aids Research Center Defensins: use as antiviral agents
US7528107B2 (en) 2005-11-30 2009-05-05 Auburn University Methods of treating inflammation in mammalian tissues comprising administering human alpha-defensins
WO2007081486A2 (en) 2005-12-15 2007-07-19 Ventria Bioscience Oral administration of defensins to treat intestinal diseases
WO2007133373A2 (en) 2006-05-01 2007-11-22 England Robert L TNF-α VACCINE FOR TREATING DISEASE CONDITIONS MEDIATED BY PATHOLOGICAL TNF-α
AU2007262776A1 (en) * 2006-06-20 2007-12-27 Lipopeptide Ab Use cathelicidin antimicrobial protein (hCAP18 ) as anticancer agent
WO2008115390A2 (en) 2007-03-16 2008-09-25 The Hamner Institutes For Health Sciences Methods of using defensins to treat diabetes
MX2010008024A (es) 2008-02-01 2010-12-21 Ascendis Pharma As Profarmaco que comprende un enlazador que se puede separar por si mismo.
EA201170219A1 (ru) 2008-07-18 2011-08-30 Новозимс Эдениум Байотек А/С Лечение воспалительных заболеваний кишечника бета-дефенсинами млекопитающих
AP2011005537A0 (en) 2008-07-18 2011-02-28 Novozymes Adenium Biotech As Treatment of inflammatory diseases with mammal beta defensins.
KR101722961B1 (ko) 2009-02-11 2017-04-04 알부메딕스 에이/에스 알부민 변이체 및 접합체
US8410049B2 (en) 2009-10-28 2013-04-02 Cebix Methods and kits for preventing hypoglycemia
US20110311601A1 (en) 2010-06-22 2011-12-22 Michael Kleine Antimicrobial medical devices
DE102010040153A1 (de) 2010-09-02 2012-03-08 Robert Bosch Gesellschaft Für Medizinische Forschung Mbh Stoffkombination zur Behandlung von entzündlichen oder infektiösen Erkrankungen
US20140220134A1 (en) * 2011-06-24 2014-08-07 Astrazeneca Pharamceuticals LP Method for treating diabetes with extended release formulation of glp-1 receptor agonists
WO2013006692A2 (en) * 2011-07-06 2013-01-10 The General Hospital Corporation Methods of treatment using a pentapeptide derived from the c-terminus of glucagon-like peptide 1 (glp-1)
US9217021B2 (en) * 2011-07-08 2015-12-22 Defensin Therapeutics Aps Oral treatment of inflammatory bowel disease
US20130052213A1 (en) 2011-08-19 2013-02-28 Novozymes A/S Novel immunomodulatory peptide
WO2014037373A1 (en) 2012-09-07 2014-03-13 Sanofi Fusion proteins for treating a metabolic syndrome
KR20180121489A (ko) 2016-01-26 2018-11-07 디펜신 테라퓨틱스 에이피에스 장내 미생물을 조절하는 방법

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104971343A (zh) * 2015-07-13 2015-10-14 韩源平 防御素在制备治疗代谢综合征药物方面的应用
CN105504063A (zh) * 2015-10-19 2016-04-20 中国医学科学院医药生物技术研究所 一类防御素-白蛋白的抗肿瘤融合蛋白及其制备和应用
CN108026130A (zh) * 2016-07-30 2018-05-11 邦泰生物工程(深圳)有限公司 一种制备烟酰胺单核苷酸的方法2
CN114075585A (zh) * 2020-08-18 2022-02-22 弈柯莱生物科技(上海)股份有限公司 一种β-烟酰胺单核苷酸的制备方法
CN112795606A (zh) * 2021-04-14 2021-05-14 深圳瑞德林生物技术有限公司 一种β-烟酰胺单核苷酸的酶催化合成方法
CN114107160A (zh) * 2021-12-27 2022-03-01 浙江工业大学 一种烟酰胺核糖激酶基因工程菌及其应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"Virucidal activity of human a- and b-defensins against hepatitis C virus genotype 4";Ehab H. Mattar et al.;《Mol. BioSyst.》;20160607;第12卷;第2785-2797页 *

Also Published As

Publication number Publication date
JP2019514908A (ja) 2019-06-06
EP3448409A1 (en) 2019-03-06
US20190192626A1 (en) 2019-06-27
BR112018071972A2 (pt) 2019-02-26
CA3022497A1 (en) 2017-11-02
US12076368B2 (en) 2024-09-03
PL3448409T3 (pl) 2026-02-23
AU2017258242A1 (en) 2018-11-29
CN109414474A (zh) 2019-03-01
RU2018141326A3 (https=) 2020-08-06
WO2017186250A1 (en) 2017-11-02
ES3057685T3 (en) 2026-03-04
EP3448409B1 (en) 2025-12-03
EP3448409C0 (en) 2025-12-03
AU2017258242B2 (en) 2024-04-04
KR20190003592A (ko) 2019-01-09
SG11201809086YA (en) 2018-11-29
KR102465341B1 (ko) 2022-11-09
RU2740913C2 (ru) 2021-01-21
RU2018141326A (ru) 2020-05-29

Similar Documents

Publication Publication Date Title
JP6890135B2 (ja) 腸内微生物叢を調節するための方法
JP7015610B2 (ja) インスリン抵抗性のための改善されたペプチドの調合薬
CN109414474B (zh) 肝脏、胆道和胰腺障碍的治疗
ES2915851T3 (es) Péptidos quiméricos de FGF19 para usar en el tratamiento de trastornos de ácidos biliares
JP6552117B2 (ja) 敗血症の予防治療剤
JP2021185178A (ja) 胆汁酸に関係した障害の治療方法
Jiang et al. Oral administration of soybean peptide Vglycin normalizes fasting glucose and restores impaired pancreatic function in Type 2 diabetic Wistar rats
US20230040594A1 (en) Milk-derived polypeptide derivative, composition and method for preventing and treating obesity
US20180280480A1 (en) Compositions and peptides having dual glp-1r and glp-2r agonist activity
BRPI0610091B1 (pt) Análogo de peptídeo 2 tipo glucagon (glp-2), composição farmacêutica, uso de um análogo de glp-2, e, kit terapêutico
JP2007531711A5 (https=)
BR112016027595B1 (pt) Produto de peptídeos, composição farmacêutica e seus usos
KR20210040818A (ko) 글루카곤, 및 glp-1 수용체 및 gip 수용체 이중 작용제를 포함하는 조성물 및 이의 치료학적 용도
JP2014504601A (ja) 抗糖尿病ペプチドとしてのアポリポタンパク質ａｉｖ
HK40001163B (en) Methods for modulating intestinal microbiota
US20250121086A1 (en) Liver-targeted substance and use thereof
HK40075122A (en) Glucagon, composition comprising glp-1 receptor and gip receptor dual agonist and therapeutic use thereof
BR112021026561B1 (pt) Uso de uma composição farmacêutica na fabricação de um medicamento para a prevenção ou tratamento de doença hepática

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20220330

Address after: Denmark bagsvaerd

Applicant after: NOVOZYMES A/S

Address before: Copenhagen, Denmark

Applicant before: DEFENSIN THERAPEUTICS APS

TA01 Transfer of patent application right
GR01 Patent grant